FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297174590> ?p ?o ?g. }

• W4297174590 endingPage "4258" @default.
• W4297174590 startingPage "4250" @default.
• W4297174590 abstract "Abstract Background We recently showed that pharmacological inhibition of plasminogen activator inhibitor‐1 (PAI‐1) activity, based on TM5614, increases cell motility and induces the detachment of hematopoietic stem cells from their niches. In this TM5614 phase II clinical trial, we investigated whether the combination of a PAI‐1 inhibitor and tyrosine kinase inhibitors (TKIs) would induce a deep molecular response (DMR) in patients affected by chronic myeloid leukemia (CML) by quantifying BCR‐ABL1 transcripts. Methods Patients with chronic phase CML treated with a stable daily dose of TKIs for at least 1 year and yielding a major molecular response (MMR) but not achieving MR 4.5 were eligible for this study. After inclusion, patients began to receive TM5614 as well as a TKI. The primary objective was an evaluation of the cumulative incidence of patient progression from an MMR/MR 4 to MR 4.5 by 12 months. Results Thirty‐three patients were enrolled in the study. The median age was 59.0 years and 58% were male. No Sokal high‐risk patients were enrolled in this trial. The median TKI treatment duration was 4.8 years. At the start of this study, seven patients and 26 patients received imatinib and second‐generation TKIs, respectively. The cumulative MR 4.5 incidence by 12 months was 33.3% (95% confidence interval, 18.0%–51.8%). The cumulative MR 4.5 spontaneous conversion over 12 months was estimated as 8% with TKIs alone based on historical controls. The halving time of BCR‐ABL1 at 2 months was significantly shorter for patients who achieved an MR 4.5 , by 12 months than for the other patients (cutoff value: 48 days; sensitivity: 0.80; specificity: 0.91; ROC‐AUC: 0.83). During this study, bleeding events and abnormal coagulation related to the drug were not reported, and TM5614 was found to be highly safe. Conclusion TM5614 combined with TKI was well tolerated and induced MR 4.5 in more patients than stand‐alone TKI treatment." @default.
• W4297174590 created "2022-09-27" @default.
• W4297174590 creator A5013112899 @default.
• W4297174590 creator A5013300942 @default.
• W4297174590 creator A5042750898 @default.
• W4297174590 creator A5053502496 @default.
• W4297174590 creator A5060770246 @default.
• W4297174590 creator A5074346318 @default.
• W4297174590 creator A5077166961 @default.
• W4297174590 creator A5081301408 @default.
• W4297174590 creator A5090933484 @default.
• W4297174590 date "2022-09-23" @default.
• W4297174590 modified "2023-10-17" @default.
• W4297174590 title "Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor‐1 inhibitor <scp>TM5614</scp> combined with a tyrosine kinase inhibitor" @default.
• W4297174590 cites W1789876634 @default.
• W4297174590 cites W1799579309 @default.
• W4297174590 cites W1969038776 @default.
• W4297174590 cites W1981975508 @default.
• W4297174590 cites W1987239635 @default.
• W4297174590 cites W2019633460 @default.
• W4297174590 cites W2064367288 @default.
• W4297174590 cites W2112817157 @default.
• W4297174590 cites W2117356576 @default.
• W4297174590 cites W2122224021 @default.
• W4297174590 cites W2138827805 @default.
• W4297174590 cites W2189113171 @default.
• W4297174590 cites W2260921597 @default.
• W4297174590 cites W2343369927 @default.
• W4297174590 cites W2397234997 @default.
• W4297174590 cites W2473480037 @default.
• W4297174590 cites W2528188718 @default.
• W4297174590 cites W2560342075 @default.
• W4297174590 cites W2565130792 @default.
• W4297174590 cites W2587781815 @default.
• W4297174590 cites W2754183140 @default.
• W4297174590 cites W2802371729 @default.
• W4297174590 cites W2823346501 @default.
• W4297174590 cites W2950308848 @default.
• W4297174590 cites W2991317364 @default.
• W4297174590 cites W3003280662 @default.
• W4297174590 cites W3009751715 @default.
• W4297174590 cites W3048549544 @default.
• W4297174590 cites W3092607363 @default.
• W4297174590 cites W3119368005 @default.
• W4297174590 cites W3162348680 @default.
• W4297174590 cites W3214161691 @default.
• W4297174590 cites W4200454229 @default.
• W4297174590 cites W4297174590 @default.
• W4297174590 doi "https://doi.org/10.1002/cam4.5292" @default.
• W4297174590 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36151699" @default.
• W4297174590 hasPublicationYear "2022" @default.
• W4297174590 type Work @default.
• W4297174590 citedByCount "1" @default.
• W4297174590 countsByYear W42971745902022 @default.
• W4297174590 crossrefType "journal-article" @default.
• W4297174590 hasAuthorship W4297174590A5013112899 @default.
• W4297174590 hasAuthorship W4297174590A5013300942 @default.
• W4297174590 hasAuthorship W4297174590A5042750898 @default.
• W4297174590 hasAuthorship W4297174590A5053502496 @default.
• W4297174590 hasAuthorship W4297174590A5060770246 @default.
• W4297174590 hasAuthorship W4297174590A5074346318 @default.
• W4297174590 hasAuthorship W4297174590A5077166961 @default.
• W4297174590 hasAuthorship W4297174590A5081301408 @default.
• W4297174590 hasAuthorship W4297174590A5090933484 @default.
• W4297174590 hasBestOaLocation W42971745901 @default.
• W4297174590 hasConcept C121608353 @default.
• W4297174590 hasConcept C126322002 @default.
• W4297174590 hasConcept C143998085 @default.
• W4297174590 hasConcept C203014093 @default.
• W4297174590 hasConcept C2777583451 @default.
• W4297174590 hasConcept C2778729363 @default.
• W4297174590 hasConcept C2778820342 @default.
• W4297174590 hasConcept C2911091166 @default.
• W4297174590 hasConcept C3019892230 @default.
• W4297174590 hasConcept C71924100 @default.
• W4297174590 hasConcept C88879693 @default.
• W4297174590 hasConcept C90924648 @default.
• W4297174590 hasConceptScore W4297174590C121608353 @default.
• W4297174590 hasConceptScore W4297174590C126322002 @default.
• W4297174590 hasConceptScore W4297174590C143998085 @default.
• W4297174590 hasConceptScore W4297174590C203014093 @default.
• W4297174590 hasConceptScore W4297174590C2777583451 @default.
• W4297174590 hasConceptScore W4297174590C2778729363 @default.
• W4297174590 hasConceptScore W4297174590C2778820342 @default.
• W4297174590 hasConceptScore W4297174590C2911091166 @default.
• W4297174590 hasConceptScore W4297174590C3019892230 @default.
• W4297174590 hasConceptScore W4297174590C71924100 @default.
• W4297174590 hasConceptScore W4297174590C88879693 @default.
• W4297174590 hasConceptScore W4297174590C90924648 @default.
• W4297174590 hasFunder F4320311405 @default.
• W4297174590 hasIssue "4" @default.
• W4297174590 hasLocation W42971745901 @default.
• W4297174590 hasLocation W42971745902 @default.
• W4297174590 hasLocation W42971745903 @default.
• W4297174590 hasOpenAccess W4297174590 @default.
• W4297174590 hasPrimaryLocation W42971745901 @default.
• W4297174590 hasRelatedWork W1921369781 @default.
• W4297174590 hasRelatedWork W1924236513 @default.

• next